Celldex Therapeutics CLDX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's accrued expenses?
- Celldex Therapeutics (CLDX) reported accrued expenses of $1.23M in Q1 2026.
- How has Celldex Therapeutics's accrued expenses changed year-over-year?
- Celldex Therapeutics's accrued expenses decreased by 25.6% year-over-year, from $1.65M to $1.23M.
- What is the long-term trend for Celldex Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accrued expenses has grown at a -18.3% compound annual growth rate (CAGR), from $3.37M to $1.23M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.